Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488754 | 0.92 | SLC6A5 (0.42) | KMT2AMEN1LGALS3LGALS9LGALS7; LGALS7B | |
| SCHEMBL23488648 | 0.87 | CA2 (0.49) | KMT2AMEN1LGALS3CA1CA2 | |
| SCHEMBL23488573 | 0.87 | CA2 (0.49) | KMT2AMEN1LGALS3CA1CA2 | |
| SCHEMBL23488688 | 0.87 | PTPN1 (0.44) | LGALS3CA1CA2CA9MMP9 | |
| SCHEMBL23488653 | 0.86 | CA1 (0.42) | KMT2AMEN1LGALS3LGALS9LGALS7; LGALS7B | |
| SCHEMBL23488180 | 0.82 | LGALS3 (0.44) | KMT2AMEN1LGALS3LGALS9LGALS7; LGALS7B | |
| SCHEMBL23488534 | 0.79 | CA2 (0.50) | LGALS3CA1CA2CA9 | |
| SCHEMBL23488318 | 0.79 | LGALS3 (0.41) | KMT2AMEN1LGALS3LGALS9LGALS7; LGALS7B | |
| SCHEMBL23488313 | 0.79 | LGALS3 (0.43) | KMT2AMEN1LGALS3LGALS9LGALS7; LGALS7B | |
| SCHEMBL23488501 | 0.76 | CA1 (0.52) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | KMT2A 4555/4885MEN1 1749/4885LGALS3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.